Wegovy product information: what it is, how it works, and what to expect

You've heard about Wegovy and you want to know what it actually is

It makes sense to start here, because the name gets used loosely. Wegovy is the brand name for semaglutide at weight-management doses, manufactured by Novo Nordisk and supplied as a pre-filled injection pen you use once a week. It is not the same product as Ozempic — which is also semaglutide, but at lower doses licensed for type 2 diabetes. The Wegovy overview on our site covers this distinction in more detail, but the short version is that the two products have different licences, different approved doses, and different intended patient groups.

The mechanism is well understood. Semaglutide binds to GLP-1 receptors in the brain and gut, reducing appetite signals and slowing gastric emptying. You feel full sooner, stay full longer, and over time take in less food without the constant mental effort of resisting hunger. This is not a stimulant or a fat-blocker; it works by engaging hormonal pathways the body already has. If you want to go deeper on how the drug works and what to expect from treatment, our Wegovy information page is a good place to read alongside any product information sheet, and the NHS also provides a clear summary on its semaglutide medicines page.

Wegovy is a Black Triangle (▼) medicine in the UK, meaning the MHRA requires additional monitoring while post-market safety data continues to accumulate. That is standard for newer medicines and does not indicate an unusual safety profile, it simply means reporting is more closely tracked.

The dose schedule and what the titration period is actually for

Treatment does not begin at the maintenance dose. The starting point is 0.25 mg per week, and the prescriber titrates upward roughly every four weeks through 0.5 mg, 1.0 mg and 1.7 mg before reaching the 2.4 mg maintenance dose. If you want a fuller breakdown of the schedule, the Wegovy information sheet on our site covers each step.

The gradual increase exists primarily to give your digestive system time to adjust. Nausea, loose stools and indigestion are the most commonly reported side effects, and they tend to be most noticeable when a new dose level starts, then settle within a week or two for most people. Rushing the titration does not improve weight-loss results; it mostly increases the chance of side effects that make treatment harder to stick with.

In April 2026, the MHRA approved a dedicated 7.2 mg single-dose weekly pen, a higher maintenance option for adults with a BMI of 30 or above, with its own auto-dosing mechanism and built-in covered needle. Trial data at this dose reported average weight loss of around 20.7% over 72 weeks, which narrows the gap with tirzepatide (Mounjaro) results. Which product or dose level suits you is a clinical decision, not something to pre-decide from product information alone. Our semaglutide information page gives broader context on where the evidence currently sits.

What the evidence shows, and what it does not promise

The pivotal data for Wegovy at 2.4 mg comes from the STEP programme. STEP 1, published in the New England Journal of Medicine, followed 1,961 adults without diabetes over 68 weeks; those on semaglutide 2.4 mg achieved an average body-weight reduction of approximately 15%, compared with around 2.4% on placebo, alongside a reduced-calorie diet and increased activity. That is a population average across people with very different starting weights and health profiles. Some people lost considerably more; some lost less.

Clinical trials tell you what is likely on balance, not what will happen for you specifically. Weight loss depends on adherence to the treatment schedule, how closely you follow the accompanying lifestyle support, and individual biology. For context on how Wegovy's results compare with those of tirzepatide, the Wegovy product comparison page covers the SURMOUNT-5 head-to-head trial evidence. NICE's appraisal of semaglutide (TA875) is also worth reviewing if you want to understand how the evidence translated into NHS recommendations.

One practical note worth raising here: Wegovy is prescribed alongside, not instead of, dietary changes and increased activity. The trial participants received structured lifestyle support throughout. That context matters when reading the results.

What happens once a prescription is issued (and what the treatment actually looks like day to day

If a prescriber approves treatment, the pen ships the same day for orders placed before noon, arriving the next working day via DPD in plain, unbranded packaging) no logos, nothing to hint at the contents. Inside the box is a pre-filled pen, a package leaflet, and a brief tracking notification you will already have on your phone before it lands on the doorstep. You keep the pen in the fridge between uses; the leaflet specifies the exact room-temperature window for travel or if refrigeration is temporarily unavailable, and that is the right place to confirm those details rather than relying on a secondary source.

Injection sites are the abdomen, thigh or upper arm; rotating the site each week reduces the chance of localised skin reactions. Side effects to watch carefully include signs of pancreatitis (severe stomach pain that spreads to the back, with or without vomiting) for which you should get medical help promptly rather than waiting for a scheduled review. The Yellow Card scheme at yellowcard.mhra.gov.uk is the right place to report any suspected side effect, and doing so genuinely helps build the post-market safety picture for all patients.

A repeat order is not automatic. At nume, every repeat is clinically re-reviewed before dispatch. If you have questions between orders, the support team is available seven days a week. If you are weighing up cost as part of your decision, the context on Wegovy pricing in the UK explains what legitimate private treatment typically includes and why headline prices can mislead.

When you are ready to talk through whether Wegovy is the right fit for you, start your free consultation and a GPhC-registered prescriber will review your details the same day.